InnoCare Pharma's novel BCL2 inhibitor Mesutoclax for the treatment of myeloid malignancies selected for oral presentation at the 2026 American ASCO Annual Meeting

InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced that multiple research achievements of its self-developed novel BCL2 inhibitor Mesutoclax (ICP-248) and novel BTK inhibitor orelabrutinib have been selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Among them,The study on Mesutoclax for the treatment of myeloid malignancies has been selected for oral presentation, while the study on Mesutoclax for the treatment of B-cell malignancies has been selected for poster presentation.

Oral presentation

Title: Safety, tolerability, and efficacy of Mesutoclax (ICP-248) in combination with azacitidine for the treatment of myeloid malignancies

Title: Safety, Tolerability, and Efficacy of Mesutoclax (ICP-248) in Combination with Azacitidine in Patients with Myeloid Malignancies

Abstract Number: 6506

Session: Oral Abstract - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplantation

Oral Abstract Session – Hematologic Malignancies: Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplantation

Central Daylight Time (CDT): Tuesday, June 2, 2026, from 9:45 AM to 12:45 PM

Presenter: Professor Hua Feng Wang

Poster Presentation 1

Title: Efficacy and safety of Mesutoclax (ICP-248) in combination with orelabrutinib for the treatment of B-cell malignancies: A pooled analysis

Title: Efficacy and Safety of Mesutoclax (ICP-248) in Combination with Orelabrutinib in Patients with B-Cell Malignancies: A pooled analysis

Abstract Number: 7073

Session: Poster - Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Poster Session - Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Central Daylight Time: Monday, June 1, 2026, from 9:00 AM to 12:00 PM

Presenter: Professor Zhiming Li

Poster Presentation 2

Title: Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma

Title: Efficacy, Safety, and Genetic Analysis of Orelabrutinib Combined with Rituximab as First-Line Systemic Treatment for Marginal Zone Lymphoma

Abstract Number: 7059

Breakout Session: Poster - Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Poster Session - Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Central Daylight Time: Monday, June 1, 2026, from 9:00 AM to 12:00 PM

Presenter: Professor Li Xian

The 2026 ASCO Annual Meeting will take place from May 29 to June 3, 2026, in Chicago. The ASCO Annual Meeting is a prestigious academic exchange event in the global oncology field, showcasing cutting-edge clinical oncology research achievements and cancer treatment technologies on an international level.

34K Views